CLAIMS

1. Use of at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive *Escherichia coli* strain in the manufacture of a medicament for treating inflammatory bowel disease in a subject in need thereof, wherein the medicament is to be administered to the subject.

2. The use according to claim 1 wherein the adherent-invasive *Escherichia coli* strain is present in one or more of the intestinal parts (small and large) of the subject.

3. The use according to claim 1 wherein the adherent-invasive *Escherichia coli* strain is LF82, 07081, 07082, 07076 or 06075~~a strain depicted in Table 1 herein or a strain depicted in Table 2 of *Darfeuille-Michaud et al. (2004), Gastroenterology 127:412-421*~~.

4. The use according to any one of claims 1 to 3 wherein the inflammatory bowel disease is Crohn's disease.

5. The use according to any one of claims 1 to 4 wherein the inflammatory bowel disease is ulcerative colitis.

6. The use according to any one of claims 1 to 5 wherein the at least one bacteriophage strain comprises the bacteriophage strain P1 deposited with the French National Collection of Microorganisms at the Institut Pasteur under Accession Number CNCM I-4694 or a variant thereof, wherein the variant has the same lytic activity, preferably the same lytic activity and the same phenotypic characteristics as said bacteriophage strain P1.

7. The use according to any one of claims 1 to 6 wherein the at least one bacteriophage strain comprises the bacteriophage strain P2 deposited with the French National Collection of Microorganisms at the Institut Pasteur under Accession Number CNCM I-4695 or a variant thereof, wherein the variant has the same lytic activity, preferably the same lytic activity and the same phenotypic characteristics as said bacteriophage strain P2.